Discovery of 5,7-Dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors

Alexander Sokolsky, Sarah Winterton, Keith Kennedy, Katherine Drake, Kristine Stump, Lu Huo, Yvonne Lo, Min Ye, Maryanne Covington, Sharon Diamond, Yan‐ou Yang, Sunkyu Kim, Swamy Yeleswaram, Liangxing Wu, Wenqing YaoACS 2022 · DOI

Abstract

A series of exceptionally selective CDK2 inhibitors are described. Starting from an HTS hit, we successfully scaffold hopped to a 5,7-dihydro-6<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-one core structure, which imparted a promising initial selectivity within the CDK family. Extensive further SAR identified additional factors that drove selectivity to above 200× for CDKs 1/4/6/7/9. General kinome selectivity was also greatly improved. Finally, use of <i>in vivo</i> metabolite identification allowed us to pinpoint sulfonamide dealkylation as the primary metabolite, which was ameliorated through the deuterium effect.
BibTeX
@inproceedings{sokolsky2022discovery,
  author = {Alexander Sokolsky and Sarah Winterton and Keith Kennedy and Katherine Drake and Kristine Stump and Lu Huo and Yvonne Lo and Min Ye and Maryanne Covington and Sharon Diamond and Yan‐ou Yang and Sunkyu Kim and Swamy Yeleswaram and Liangxing Wu and Wenqing Yao},
  title = {{Discovery of 5,7-Dihydro-6<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors}},
  booktitle = {ACS},
  year = {2022},
  doi = {10.1021/acsmedchemlett.2c00408},
}

Loading related content...

Figure